Acta Scientific Agriculture (ASAG)(ISSN: 2581-365X)

Case Report Volume 5 Issue 6

A Successful Treatment of Feline Panleukopenia


Bachelor Of Veterinary Science and Animal Husbandry College of Veterinary and Animal Sciences, Abudhabi, United Arab Emirates

*Corresponding Author: MEHABA CM, Bachelor of Veterinary Science and Animal Husbandry College of Veterinary and Animal Sciences, Abudhabi, United Arab Emirates.

Received: April 28, 2023; Published: May 11, 2023


This article introduces a novel approach to treating feline panleukopenia, a highly contagious and life-threatening disease in cats. Instead of relying solely on traditional supportive care such as fluid therapy, antiemetics, and antibiotics, this study explores the use of filgrastim, a granulocyte colony-stimulating factor, to improve survival rates in cats suffering from severe leukopenia and neutropenia. The case report documents the successful treatment of five domestic cats with feline panleukopenia using filgrastim in conjunction with other forms of supportive care. This promising treatment protocol has the potential to significantly improve the prognosis for cats diagnosed with this devastating illness.

Keywords: Feline; Panleukopenia


  1. Jane K Rice. “Successful Treatment of Feline Panleukopenia: A Guideline for Rescuers and Veterinarians, Part 1”. Journal of Veterinary Science and Medical Diagnosis Castle Cat Rescue, 4121 Elizabeth Ln, Fairfax, VA, USA 6.5 (2017).
  2. W Kraft., et al. “Treatment of severe Neutropenias in dogs and cats with filgrastim”. Tierärztliche Praxis (1995).
  3. Nuno Félix., et al. “Clinical use of recombinant human granulocyte colony-stimulating factor in 7 cats with natural viral panleucopenia infection”. Pratique Médicale et Chirurgicale de l Animal de Compagnie 40 (2005): 71-75.


Citation: MEHABA CM. “A Successful Treatment of Feline Panleukopenia". Acta Scientific Veterinary Sciences 5.6 (2023): 33-35.


Copyright: © 2023 MEHABA CM. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate35%
Acceptance to publication20-30 days
Impact Factor1.008

Indexed In

News and Events

Contact US